Novel Visualization of Aqueous Outflow: Uncovering Glaucoma Mechanisms and Therapeutic Targets
Principal Investigator
Tyson Kim, MD, PhD
University of California, San Francisco
San Francisco, CA, USA
About the Research Project
Program
Award Type
Standard
Award Amount
$150,000
Active Dates
July 01, 2026 - June 30, 2028
Grant ID
G2026009S
Acknowledgement
Goals
This project uses a novel imaging platform to, for the first time, non-invasively visualize and quantify aqueous drainage in the living eye with subcellular resolution, uncovering mechanisms regulating outflow and eye pressure, and identifying new targets that may enable personalized glaucoma therap
Summary
Glaucoma is the leading cause of irreversible blindness and is strongly influenced by elevated pressure and impaired fluid drainage from the eye. We developed a new imaging method that visualizes and quantifies this drainage with microscopic precision in the living eye, uncovering new insights into outflow dynamics and opening opportunities for discovery and therapeutic innovation in glaucoma.
Unique and Innovative
This proposal introduces a novel imaging platform that visualizes and quantifies aqueous drainage with subcellular resolution in the living eye. Unlike existing approaches, it enables direct, continuous, and longitudinal measurement of flow in relation to microanatomy within Schlemm’s canal and downstream drainage pathways in vivo. By revealing how outflow is organized and modulated, this platform establishes a powerful new framework for mechanistic discovery and the identification of new therapeutic targets in glaucoma.
Foreseeable Benefits
This study will establish a first-of-its-kind framework for directly visualizing and quantifying aqueous drainage dynamics in the living eye – non-invasively, continuously, and with subcellular resolution – fundamentally advancing our ability to understand how outflow is regulated and how it may fail in glaucoma. By identifying new control points in the drainage pathway, this work will open new avenues for more targeted and personalized glaucoma therapies. For the millions living with glaucoma worldwide, these advances hold the promise of new and personalized treatments that better preserve vision and quality of life.
Related Grants
National Glaucoma Research
Developing New Drugs for Glaucoma
Active Dates
January 01, 2026 - December 31, 2027
Principal Investigator
Pete Williams, PhD
Current Organization
Karolinska Institutet
Developing New Drugs for Glaucoma
Active Dates
January 01, 2026 - December 31, 2027
Principal Investigator
Pete Williams, PhD
Current Organization
Karolinska Institutet
National Glaucoma Research
Maldevelopment of Schlemm's Canal in Children with Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Revathi Balasubramanian, PhD
Current Organization
Columbia University
Maldevelopment of Schlemm's Canal in Children with Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Revathi Balasubramanian, PhD
Current Organization
Columbia University
National Glaucoma Research
Developing a New Glaucoma Treatment That Avoids Daily Drops
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Gavin Roddy, MD, PhD
Current Organization
Mayo Clinic, Rochester
Developing a New Glaucoma Treatment That Avoids Daily Drops
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Gavin Roddy, MD, PhD
Current Organization
Mayo Clinic, Rochester